BACKGROUND: The population-level impact of modifiable postmenopausal breast cancer risk factors is incompletely understood, especially regarding potential heterogeneity by estrogen receptor (ER) and progesterone receptor (PR) status. METHODS: Using data on 3074 cases and 6386 controls from a population-based case-control study of postmenopausal breast cancer conducted in Germany between 2002 and 2005, we calculated multivariable-adjusted odds ratios and population attributable risks (PARs) for modifiable and non-modifiable risk factors. We examined overall postmenopausal invasive breast cancer as well as tumor ER/PR subtypes. A bootstrap method provided estimates of 95% confidence intervals (95%CIs). RESULTS: The summary PARs (95%CIs) for non-modifiable risk factors (age at menarche, age at menopause, parity, benign breast disease, and family history of breast cancer) were 37.2% (27.1-47.2%) regarding overall invasive tumors, 36.5% (23.3-47.6%) regarding ER+/PR+ tumors, 47.9% (26.4-64.4%) regarding ER+/PR- tumors, and 31.1% (4.0-51.9%) regarding ER-/PR- tumors. Of the modifiable risk factors (hormone therapy (HT) use, physical inactivity, BMI, alcohol consumption), HT use and physical inactivity had the highest impact with PARs of 19.4% (15.9-23.2%) and 12.8% (5.5-20.8%), respectively, regarding overall invasive tumors. For ER+/PR+ tumors, the corresponding PARs were 25.3% (20.9-29.7%) and 16.6% (7.0-26.0%). The summary PARs (95%CIs) for HT use and physical inactivity together were 29.8% (21.8-36.9%) and 37.9% (30.6-46.2%) regarding overall invasive and ER+/PR+ tumors, respectively. CONCLUSIONS: The population-level impact of modifiable risk factors appears to be comparable to that of non-modifiable risk factors. Alterations in HT use and physical inactivity could potentially reduce postmenopausal invasive breast cancer incidence in Germany by nearly 30%, with the largest potential for reduction among ER+/PR+ tumors, the most frequently diagnosed subtype.
BACKGROUND: The population-level impact of modifiable postmenopausal breast cancer risk factors is incompletely understood, especially regarding potential heterogeneity by estrogen receptor (ER) and progesterone receptor (PR) status. METHODS: Using data on 3074 cases and 6386 controls from a population-based case-control study of postmenopausal breast cancer conducted in Germany between 2002 and 2005, we calculated multivariable-adjusted odds ratios and population attributable risks (PARs) for modifiable and non-modifiable risk factors. We examined overall postmenopausal invasive breast cancer as well as tumorER/PR subtypes. A bootstrap method provided estimates of 95% confidence intervals (95%CIs). RESULTS: The summary PARs (95%CIs) for non-modifiable risk factors (age at menarche, age at menopause, parity, benign breast disease, and family history of breast cancer) were 37.2% (27.1-47.2%) regarding overall invasive tumors, 36.5% (23.3-47.6%) regarding ER+/PR+ tumors, 47.9% (26.4-64.4%) regarding ER+/PR- tumors, and 31.1% (4.0-51.9%) regarding ER-/PR- tumors. Of the modifiable risk factors (hormone therapy (HT) use, physical inactivity, BMI, alcohol consumption), HT use and physical inactivity had the highest impact with PARs of 19.4% (15.9-23.2%) and 12.8% (5.5-20.8%), respectively, regarding overall invasive tumors. For ER+/PR+ tumors, the corresponding PARs were 25.3% (20.9-29.7%) and 16.6% (7.0-26.0%). The summary PARs (95%CIs) for HT use and physical inactivity together were 29.8% (21.8-36.9%) and 37.9% (30.6-46.2%) regarding overall invasive and ER+/PR+ tumors, respectively. CONCLUSIONS: The population-level impact of modifiable risk factors appears to be comparable to that of non-modifiable risk factors. Alterations in HT use and physical inactivity could potentially reduce postmenopausal invasive breast cancer incidence in Germany by nearly 30%, with the largest potential for reduction among ER+/PR+ tumors, the most frequently diagnosed subtype.
Authors: Gertraud Maskarinec; Simone Jacobs; Song-Yi Park; Christopher A Haiman; Veronica W Setiawan; Lynne R Wilkens; Loïc Le Marchand Journal: Cancer Epidemiol Biomarkers Prev Date: 2017-01-13 Impact factor: 4.254
Authors: Karla Kerlikowske; Charlotte C Gard; Jeffrey A Tice; Elad Ziv; Steven R Cummings; Diana L Miglioretti Journal: J Natl Cancer Inst Date: 2016-12-31 Impact factor: 13.506
Authors: Rulla M Tamimi; Donna Spiegelman; Stephanie A Smith-Warner; Molin Wang; Mathew Pazaris; Walter C Willett; A Heather Eliassen; David J Hunter Journal: Am J Epidemiol Date: 2016-12-06 Impact factor: 4.897
Authors: Heather Greenlee; Christine L Sardo Molmenti; Laura Falci; Ross Ulmer; Sandra Deming-Halverson; Lisa A DeRoo; Dale P Sandler Journal: Breast Cancer Res Treat Date: 2016-03-26 Impact factor: 4.872
Authors: Anika Hüsing; Anne S Quante; Jenny Chang-Claude; Krasimira Aleksandrova; Rudolf Kaaks; Ruth M Pfeiffer Journal: Cancer Causes Control Date: 2020-04-06 Impact factor: 2.506
Authors: Natalie J Engmann; Marzieh K Golmakani; Diana L Miglioretti; Brian L Sprague; Karla Kerlikowske Journal: JAMA Oncol Date: 2017-09-01 Impact factor: 31.777